[The long-term observation period of pregnant women after acute gestational pyelonephritis].

Abstract

Urinary tract infections, in particular acute gestational pyelonephritis (AGP) determine a high risk of developing various complications of pregnancy and childbirth. The development of new medical technologies for the treatment of AGP remains relevant. It has not only high direct effectiveness, but also shows a distinct impact of secondary prevention of pyelonephritis exacerbations and a fetoprotective effect. An objective evidence for these effects is the study of long-term treatment outcomes.

Objective: To evaluate the general condition of pregnant women in a randomized controlled study of the long-term observation period who underwent acute gestational pyelonephritis, birth results, quality of life of the patients and vitality of the newborns.

Material and methods: The study included 93 women at the age of 16 to 40 years old who underwent AGP. They were divided into two groups by simple randomization: the main/MG (46 people) and the control/CG (47 people). The control group of the patients was prescribed the drug standard; the main one had intravenous ozone therapy (OT) in addition to it.

Results: In the MG the patients had significant differences (p<0.05-0.001) with women of the CG in such indicators as: repeated relapses of gestational pyelonephritis (4.5 times), late gestational toxicosis (2.6 times), the number of newborns with normal growth and weight parameters (1.9 times), bacteriuria (3.0 times), leukocytouria (4.0 times), medical care for the main disease (5.0 times), outpatient treatment (8.0 times) and quality of life indicators - physical and social activity as well as general health.

Conclusion: An additional prescription in the standard of care for patients with AGP based on intravenous administration of an ozone-oxygen mixture significantly improves the long-term results of the therapy and the quality of life of patients who have undergone AGP, and also has a distinct fetoprotective effect. The absence of adverse reactions with all the patients including in the long-term follow-up period indicates the safety of a new complex of restorative treatment for AGP.